Dr. Fowler on FLIPI Scoring System in Follicular Lymphoma

Video

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the FLIPI scoring system in follicular lymphoma.

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the FLIPI scoring system in follicular lymphoma.

FLIPI predicts disease progression in groups of patients through factors of low hemoglobin levels, stage III/IV disease, number of nodal sites, patient age, and amount of lactate dehydrogenase (LDH). It is used to determine if a group of patients will have a worse outcome overall.

Fowler emphasizes that this system looks at the group as a whole. This means that individual patients who may have a better outcome can exist within a test group—but there isn’t a way to determine who those patients are.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,